SYMPLICITY SPYRAL™ RENAL DENERVATION (RDN) SYSTEM
Patient selection
and access
The Symplicity™ blood pressure procedure — which uses the Symplicity Spyral™ RDN system — provides another treatment option for patients struggling with hypertension. Read on to understand which patients might benefit from this procedure, how to explain it to them, and how to help them access care.
Patient selection considerations
When thinking about which of your hypertension patients could benefit from the Symplicity™ procedure, consider those who:
Have uncontrolled hypertension
Consider patients where lifestyle modifications and antihypertensive medications haven’t adequately controlled blood pressure.
Are willing to undergo an interventional procedure
Consider patients who opt for the Symplicity™ procedure following shared decision-making and an attempt at lifestyle modifications and medical therapy.
30% of patients
would be willing to consider an interventional approach to manage hypertension versus an additional medication.1
What patients can expect following the procedure
Patients on one or more antihypertensive medications who underwent the Symplicity™ procedure as a complementary treatment (N = 199) experienced the following reductions in office systolic blood pressure at six months2,3:
- > 61% of patients responded with a reduction of > 5 mmHg
- > 51% of patients responded with a reduction of > 10 mmHg
- > 37% of patients responded with a reduction of > 15 mmHg
- > 24% of patients responded with a reduction of > 20 mmHg
Browse product and procedure details and download resources so you can learn more about this complementary treatment for your patients struggling with hypertension.
Results may vary.
3x
as many patients vs. sham were able to get their blood pressure under control (< 140 mmHg) at 6 months.2
(20% RDN vs. 6% sham, p = 0.001)
Helping your patients access care
If you think you‘ve identified a potential patient for the Symplicity™ procedure, first review the benefits and risks with them. Use the following resources to support discussions with your patients and help them understand the procedure:
Find a specialist
Find physicians who have demonstrated sufficient experience with the Symplicity Spyral™ system used during the Symplicity™ procedure.
Learn more about the Symplicity™ procedure.
Sign up for email so we can send other relevant information and resources directly to your inbox.
Related pages
Review clinical evidence.
The Symplicity Spyral™ RDN system is backed by multiple sham-controlled trials and a real-world registry.
Establish a Symplicity™ RDN program.
Understand the suggested framework needed to incorporate the procedure into your practice.
Understand coverage.
Use our coding, coverage, and payment resources to help navigate the reimbursement process.
1. Kandzari DE, Weber MA, Poulos C, et al. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997.
2. Kandzari D, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medication. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
3. CSDP sponsor executive summary: Symplicity Spyral™ renal denervation system. Medtronic. Available at: fda.gov/media/171412/download. Accessed on November 17, 2023.